• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Buprenorphine implants more likely than sublingual delivery to prevent opioid relapse

byDaniel FisherandMichael Milligan
July 19, 2016
in Chronic Disease, Psychiatry, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients using sublingual buprenorphine without previous relapse were more likely to remain relapse free if administered subdermal buprenorphine implants, compared to those who continued sublingual delivery.

2. Intensity of opioid craving and rates of adverse effects were similar between groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Opioid abuse remains a significant medical and public health issue. While combined medical treatment and counseling reduces the rates of relapse, adherence to medication therapy is crucial for success. Therefore, methods to increase adherence are likely to increase the rate of positive outcomes. In this double-blind, multisite, randomized, controlled trial, patients who were relapse free for 24 weeks using sublingual buprenorphine were administered either subdermal buprenorphine (treatment group) or continued sublingual buprenorphine (control group) and followed for 6 months. There were significantly more patients in the treatment group remaining relapse free after 6 month compared to controls. Additionally, buprenorphine implants were found to be superior to sublingual buprenorphine on certain measures of adherence, and similar on many others, even after extensive sensitivity analyses. There was no difference between groups in terms of serious adverse events nor intensity of opioid cravings.

It’s important to state that this trial was conducted with participants that had already showed prolonged abstinence with sublingual buprenorphine, which resulted in relatively low relapse rates overall when compared to other studies. Therefore, it’s possible that subdermal buprenorphine implants may be even more effective in a general population. Still, this trial was not sufficiently powered to determine if there were definitively similar rates of adverse effects, and more studies will be needed to confirm this finding.

Click to read the study, published today in JAMA

Relevant Reading: Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial

RELATED REPORTS

Reinfection with hepatitis C virus is highest immediately after treatment in patients on opioid agonist therapy

Prenatal exposure to opioids and its potential associations with subsequent academic performance

#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

In-Depth [randomized controlled trial]: A total of 177 participants taking sublingual buprenorphine with at least 24 weeks of abstinence from opioids were recruited to this multisite, double blind, randomized, controlled trial. Patients were randomly assigned to receive either subdermal buprenorphine implants and placebo sublingual medication (treatment group) or placebo subdermal implants and sublingual buprenorphine (control group) and followed for 6 months to determine the rates of relapse. With 93% of patients in both groups completing the trial, a total of 87.7% of the control group and 96.4% of the treatment group remained free from opioid use for at least 4 of the 6 months. This difference achieved statistical significance for both non-inferiority (p < 0.001) and superiority (p = 0.03) of the subdermal buprenorphine implants. Multiple sensitivity analyses confirmed non-inferiority of treatment. At 6 months, the treatment group showed higher cumulative abstinence rates than controls (85.7% vs 71.9%; HR 13.8, p = 0.03) with a number-needed-to-treat of 7.25. There was no significant differences between intensity of cravings or withdrawal measures using self-reported measures, the Subjective Opioid Withdrawal Scale (SOWS), and Clinical Opioid Withdrawal Scales (COWS). Three patients on sublingual buprenorphine experienced serious adverse events (biliary colic, chronic cholecystitis, bronchitis) as well as three patients on buprenorphine implants (convulsions, worsening Bipolar I Disease, muscle spasms).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: opioids
Previous Post

Adolescent bariatric surgery associated with improved mobility and reduced musculoskeletal pain

Next Post

HPV awareness not linked to vaccination in high-risk population

RelatedReports

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Chronic Disease

Reinfection with hepatitis C virus is highest immediately after treatment in patients on opioid agonist therapy

August 25, 2022
Characteristic differences between young children and adolescents who die by suicide
Obstetrics

Prenatal exposure to opioids and its potential associations with subsequent academic performance

July 25, 2022
#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication
StudyGraphics

#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

June 11, 2022
#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia
StudyGraphics

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

May 4, 2022
Next Post
Decreased prevalence of HPV among vaccinated young females

HPV awareness not linked to vaccination in high-risk population

Postextubation administration of high-flow oxygen leads to reduced reintubation and respiratory failure

Some components of ventilator bundles may not improve patient outcomes

Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

In vitro fertilization not linked with higher risk of breast cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options